Table Info

Table 2.

Clinical trials with drug targeting metabolic reprogramming

Metabolic target	Experimental drug	Combination drug	Cancer type	Reference
Anti-mitochondrial (tricarboxylic acid cycle)	Devimistat	Chemotherapy	Pancreatic cancer	[132]
Glutaminase inhibitor	Telaglenastat	Cabozantinib	Renal clear-cell cancer	[133]
IDO1	Epacadostat	Pembrolizumab	Melanoma	[134]
Pegylated recombinant human hyaluronidase	Pegvorhyaluronidase alfa (PEGPH20)	Chemotherapy	Pancreatic cancer	[139]
OXPHOS inhibitor	IACS-010759	None	Myeloid leukemia and advanced solid tumors	[140]
Arginase inhibitor	INCB001158	Retifanlimab	Advanced solid tumors	[142]

IDO1: inoleamine-2, 3-dioxygenase; OXPHOS: oxidative phosphorylation

Declarations

Author contributions

LCG: Data curation, Visualization, Investigation, Writing—original draft, Writing—review & editing. MPK: Supervision, Investigation. SCC: Conceptualization, Methodology, Software. BCO: Methodology, Writing—review & editing, Validation. VPB: Data curation, Validation, Investigation, Writing—review & editing.

Conflicts of interest

Luis Cabezón-Gutiérrez reports he received payment for presentations of Roche, Astra Zeneca, Brystol Myers Squibb, Merck Serono, Ipsen Pharma, Grunenthal, Kyowa Kirin, Pfizer and Eisai and received support for attending meetings from Roche, Merck. Eli Lilly, Bristol-Myers Squibb and Nutricia. Vilma Pacheco-Barcia reports receiving grants as awards from Merck, FSEOM, and Pfizer, as well as payments for presentations from Merck, Eli Lilly, Eisai, and Pierre Fabre. She has also received support for attending meetings from Roche, Eli Lilly, Bristol-Myers Squibb, Merck, Amgen, Merck Sharp & Dohme, and Nutricia. Additionally, she participated in advisory boards for Advanced Accelerator Applications (a Novartis company) and Nutricia. Sara Custodio-Cabello has received honoraria (outside of this submitted study) from Fresenius, Astellas Pharma, Merck and Abbott and received support for attending meetings from Pierre-Fabre and Amgen. Magda Palka-Kotlowska has received payment for presentations of Pfizer, Devon, Pharmamar, and Esteve and received support for attending meetings from Pfizer and Novartis. Beatriz Chacón-Ovejero have no conflicts of interest to declare. All the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17:351–9. [DOI] [PubMed] [PMC]

Callao V, Montoya E. Toxohormone-like factor from microorganisms with impaired respiration. Science. 1961;134:2041–2. [DOI] [PubMed]

Zhang J, Yang J, Lin C, Liu W, Huo Y, Yang M, et al. Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer. Theranostics. 2020;10:8400–14. [DOI] [PubMed] [PMC]

Domiński A, Krawczyk M, Konieczny T, Kasprów M, Foryś A, Pastuch-Gawołek G, et al. Biodegradable pH-responsive micelles loaded with 8-hydroxyquinoline glycoconjugates for Warburg effect based tumor targeting. Eur J Pharm Biopharm. 2020;154:317–29. [DOI] [PubMed]

Hurley HJ, Dewald H, Rothkopf ZS, Singh S, Jenkins F, Deb P, et al. Frontline Science: AMPK regulates metabolic reprogramming necessary for interferon production in human plasmacytoid dendritic cells. J Leukoc Biol. 2021;109:299–308. [DOI] [PubMed]

Guerra L, Bonetti L, Brenner D. Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy. Cell Rep. 2020;32:107848. [DOI] [PubMed]

Rodríguez C, Puente-Moncada N, Reiter RJ, Sánchez-Sánchez AM, Herrera F, Rodríguez-Blanco J, et al. Regulation of cancer cell glucose metabolism is determinant for cancer cell fate after melatonin administration. J Cell Physiol. 2021;236:27–40. [DOI] [PubMed]

Lapa B, Gonçalves AC, Jorge J, Alves R, Pires AS, Abrantes AM, et al. Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target. Med Oncol. 2020;37:72. [DOI] [PubMed]

Chen B, Gao A, Tu B, Wang Y, Yu X, Wang Y, et al. Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery. Biomaterials. 2020;255:120187. [DOI] [PubMed]

10.

Hu N, Li H, Tao C, Xiao T, Rong W. The Role of Metabolic Reprogramming in the Tumor Immune Microenvironment: Mechanisms and Opportunities for Immunotherapy in Hepatocellular Carcinoma. Int J Mol Sci. 2024;25:5584. [DOI] [PubMed] [PMC]

11.

Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, et al. Apc tumor suppressor gene is the “zonation-keeper” of mouse liver. Dev Cell. 2006;10:759–70. [DOI] [PubMed]

12.

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28. [DOI] [PubMed] [PMC]

13.

Terry S, Engelsen AST, Buart S, Elsayed WS, Venkatesh GH, Chouaib S. Hypoxia-driven intratumor heterogeneity and immune evasion. Cancer Lett. 2020;492:1–10. [DOI] [PubMed]

14.

Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2:132–41. [DOI] [PubMed]

15.

Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162:1229–41. [DOI] [PubMed] [PMC]

16.

Bezwada D, Perelli L, Lesner NP, Cai L, Brooks B, Wu Z, et al. Mitochondrial complex I promotes kidney cancer metastasis. Nature. 2024;633:923–31. [DOI] [PubMed] [PMC]

17.

Bartman CR, Weilandt DR, Shen Y, Lee WD, Han Y, TeSlaa T, et al. Slow TCA flux and ATP production in primary solid tumours but not metastases. Nature. 2023;614:349–57. [DOI] [PubMed] [PMC]

18.

Pranzini E, Pardella E, Paoli P, Fendt SM, Taddei ML. Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids. Trends Cancer. 2021;7:682–99. [DOI] [PubMed]

19.

Liu Y, Zhao T, Li Z, Wang L, Yuan S, Sun L. The role of ASCT2 in cancer: A review. Eur J Pharmacol. 2018;837:81–7. [DOI] [PubMed]

20.

Halestrap AP. The monocarboxylate transporter family--Structure and functional characterization. IUBMB Life. 2012;64:1–9. [DOI] [PubMed]

21.

Huang Z, Gan J, Long Z, Guo G, Shi X, Wang C, et al. Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection. Biomaterials. 2016;90:72–84. [DOI] [PubMed]

22.

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812–9. [DOI] [PubMed]

23.

Bhagat TD, Von Ahrens D, Dawlaty M, Zou Y, Baddour J, Achreja A, et al. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Elife. 2019;8:e50663. [DOI] [PubMed] [PMC]

24.

Dodard G, Tata A, Erick TK, Jaime D, Miah SMS, Quatrini L, et al. Inflammation-Induced Lactate Leads to Rapid Loss of Hepatic Tissue-Resident NK Cells. Cell Rep. 2020;32:107855. [DOI] [PubMed] [PMC]

25.

Xia C, Liu C, He Z, Cai Y, Chen J. Metformin inhibits cervical cancer cell proliferation by modulating PI3K/Akt-induced major histocompatibility complex class I-related chain A gene expression. J Exp Clin Cancer Res. 2020;39:127. [DOI] [PubMed] [PMC]

26.

van Son KC, Verschuren L, Hanemaaijer R, Reeves H, Takkenberg RB, Drenth JPH, et al. Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. Cancers (Basel). 2023;15:1308. [DOI] [PubMed] [PMC]

27.

Piñeiro Fernández J, Luddy KA, Harmon C, O’Farrelly C. Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function. Int J Mol Sci. 2019;20:4131. [DOI] [PubMed] [PMC]

28.

Contreras-Baeza Y, Sandoval PY, Alarcón R, Galaz A, Cortés-Molina F, Alegría K, et al. Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments. J Biol Chem. 2019;294:20135–47. [DOI] [PubMed] [PMC]

29.

Zeng Z, Lan J, Lei S, Yang Y, He Z, Xue Y, et al. Simultaneous Inhibition of Ornithine Decarboxylase 1 and Pyruvate Kinase M2 Exerts Synergistic Effects Against Hepatocellular Carcinoma Cells. Onco Targets Ther. 2020;13:11697–709. [DOI] [PubMed] [PMC]

30.

Wang X, Zhang P, Deng K. MYC Promotes LDHA Expression through MicroRNA-122-5p to Potentiate Glycolysis in Hepatocellular Carcinoma. Anal Cell Pathol (Amst). 2022;2022:1435173. [DOI] [PubMed] [PMC]

31.

Fiume L, Vettraino M, Manerba M, Di Stefano G. Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. Pharmacol Res. 2011;63:328–34. [DOI] [PubMed]

32.

Daneshmandi S, Choi JE, Yan Q, MacDonald CR, Pandey M, Goruganthu M, et al. Myeloid-derived suppressor cell mitochondrial fitness governs chemotherapeutic efficacy in hematologic malignancies. Nat Commun. 2024;15:2803. [DOI] [PubMed] [PMC]

33.

Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123:3664–71. [DOI] [PubMed] [PMC]

34.

Roland CL, Arumugam T, Deng D, Liu SH, Philip B, Gomez S, et al. Cell surface lactate receptor GPR81 is crucial for cancer cell survival. Cancer Res. 2014;74:5301–10. [DOI] [PubMed] [PMC]

35.

Tao Q, Chen M, Liu Z, Xu X, Wei L, Ma S, et al. Glucose-Enhanced Tumor Oxidative Phosphorylation and the Efficacy of Hypofractionated Radiotherapy through IFN-I Pathway. Int J Radiat Oncol Biol Phys. 2024;120:e402–3. [DOI]

36.

Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology. 2017;153:812–26. [DOI] [PubMed]

37.

Bu L, Zhang Z, Chen J, Fan Y, Guo J, Su Y, et al. High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT. Gut. 2024;73:1156–68. [DOI] [PubMed]

38.

Che L, Chi W, Qiao Y, Zhang J, Song X, Liu Y, et al. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020;69:177–86. [DOI] [PubMed] [PMC]

39.

Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A. 2010;107:7455–60. [DOI] [PubMed] [PMC]

40.

Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188:21–8. [DOI] [PubMed] [PMC]

41.

Martínez-Colón GJ, Moore BB. Prostaglandin E₂as a Regulator of Immunity to Pathogens. Pharmacol Ther. 2018;185:135–46. [DOI] [PubMed] [PMC]

42.

Zhang X, Yan K, Deng L, Liang J, Liang H, Feng D, et al. Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway. Cell Transplant. 2019;28:1S–13S. [DOI] [PubMed] [PMC]

43.

Luan B, Yoon YS, Le Lay J, Kaestner KH, Hedrick S, Montminy M. CREB pathway links PGE2 signaling with macrophage polarization. Proc Natl Acad Sci U S A. 2015;112:15642–7. [DOI] [PubMed] [PMC]

44.

Lu W, Yu W, He J, Liu W, Yang J, Lin X, et al. Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. EMBO Mol Med. 2021;13:e12798. [DOI] [PubMed] [PMC]

45.

Sander WJ, O’Neill HG, Pohl CH. Prostaglandin E₂As a Modulator of Viral Infections. Front Physiol. 2017;8:89. [DOI] [PubMed] [PMC]

46.

Tang T, Scambler TE, Smallie T, Cunliffe HE, Ross EA, Rosner DR, et al. Macrophage responses to lipopolysaccharide are modulated by a feedback loop involving prostaglandin E₂, dual specificity phosphatase 1 and tristetraprolin. Sci Rep. 2017;7:4350. [DOI] [PubMed] [PMC]

47.

Buck MD, O’Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, et al. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell. 2016;166:63–76. [DOI] [PubMed] [PMC]

48.

Yadav UP, Singh T, Kumar P, Sharma P, Kaur H, Sharma S, et al. Metabolic Adaptations in Cancer Stem Cells. Front Oncol. 2020;10:1010. [DOI] [PubMed] [PMC]

49.

Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153–61. [DOI] [PubMed] [PMC]

50.

Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496:101–5. [DOI] [PubMed] [PMC]

51.

Zhang Y, Chung SF, Tam SY, Leung YC, Guan X. Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination. Cancer Lett. 2021;502:58–70. [DOI] [PubMed]

52.

Xu Y, Nijhuis A, Keun HC. RNA-binding motif protein 39 (RBM39): An emerging cancer target. Br J Pharmacol. 2022;179:2795–812. [DOI] [PubMed]

53.

Yu SJ, Ma C, Heinrich B, Brown ZJ, Sandhu M, Zhang Q, et al. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. J Hepatol. 2019;70:449–57. [DOI] [PubMed] [PMC]

54.

Wang X, Zhang Q, Zhou J, Xiao Z, Liu J, Deng S, et al. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma. J Immunother Cancer. 2023;11:e006493. [DOI] [PubMed] [PMC]

55.

Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22. [DOI] [PubMed] [PMC]

56.

Ao Du, Zhen Wang, Tengda Huang, Shuai Xue, Chuang Jiang, Guoteng Qiu, et al. Fatty acids in cancer: Metabolic functions and potential treatment. MedComm Oncol. 2023;2:e25. [DOI]

57.

Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood. 2003;101:3628–34. [DOI] [PubMed]

58.

Phelps CC, Vadia S, Boyaka PN, Varikuti S, Attia Z, Dubey P, et al. A listeriolysin O subunit vaccine is protective against Listeria monocytogenes. Vaccine. 2020;38:5803–13. [DOI] [PubMed] [PMC]

59.

Perrone F, Minari R, Bersanelli M, Bordi P, Tiseo M, Favari E, et al. The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors. J Immunother. 2020;43:196–203. [DOI] [PubMed]

60.

Raccosta L, Fontana R, Maggioni D, Lanterna C, Villablanca EJ, et al. The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J Exp Med. 2013;210:1711–28. [DOI] [PubMed] [PMC]

61.

Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 2013;5:637–45. [DOI] [PubMed] [PMC]

62.

Baek AE, Yu YA, He S, Wardell SE, Chang CY, Kwon S, et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017;8:864. [DOI] [PubMed] [PMC]

63.

Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14:113. [DOI] [PubMed]

64.

Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer. 2023;23:275–94. [DOI] [PubMed] [PMC]

65.

Ma J, Zhong M, Xiong Y, Gao Z, Wu Z, Liu Y, et al. Emerging roles of nucleotide metabolism in cancer development: progress and prospect. Aging (Albany NY). 2021;13:13349–58. [DOI] [PubMed] [PMC]

66.

Fan SJ, Kroeger B, Marie PP, Bridges EM, Mason JD, McCormick K, et al. Glutamine deprivation alters the origin and function of cancer cell exosomes. EMBO J. 2020;39:e103009. [DOI] [PubMed] [PMC]

67.

Caiola E, Colombo M, Sestito G, Lupi M, Marabese M, Pastorelli R, et al. Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation. Cells. 2020;9:1766. [DOI] [PubMed] [PMC]

68.

Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol. 2010;185:1037–44. [DOI] [PubMed] [PMC]

69.

Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, et al. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Cell. 2018;175:1780–95.e19. [DOI] [PubMed] [PMC]

70.

Hildebrand D, Heeg K, Kubatzky KF. Pasteurella multocida Toxin Manipulates T Cell Differentiation. Front Microbiol. 2015;6:1273. [DOI] [PubMed] [PMC]

71.

Cohen AS, Geng L, Zhao P, Fu A, Schulte ML, Graves-Deal R, et al. Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer. Transl Oncol. 2020;13:100828. [DOI] [PubMed] [PMC]

72.

Kami Reddy KR, Piyarathna DWB, Park JH, Putluri V, Amara CS, Kamal AHM, et al. Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer. JCI Insight. 2024;9:e172336. [DOI] [PubMed] [PMC]

73.

Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5:641–54. [DOI] [PubMed]

74.

Davel LE, Jasnis MA, de la Torre E, Gotoh T, Diament M, Magenta G, et al. Arginine metabolic pathways involved in the modulation of tumor-induced angiogenesis by macrophages. FEBS Lett. 2002;532:216–20. [DOI] [PubMed]

75.

Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat. 2013;45:251–62. [DOI] [PubMed] [PMC]

76.

Grohmann U, Mondanelli G, Belladonna ML, Orabona C, Pallotta MT, Iacono A, et al. Amino-acid sensing and degrading pathways in immune regulation. Cytokine Growth Factor Rev. 2017;35:37–45. [DOI] [PubMed]

77.

Liu H, Shen Z, Wang Z, Wang X, Zhang H, Qin J, et al. Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Sci Rep. 2016;6:21319. [DOI] [PubMed] [PMC]

78.

Cronin SJF, Seehus C, Weidinger A, Talbot S, Reissig S, Seifert M, et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature. 2018;563:564–8. [DOI] [PubMed] [PMC]

79.

Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, et al. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res. 2009;15:641–9. [DOI] [PubMed]

80.

Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37. [DOI] [PubMed] [PMC]

81.

Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016;18:84. [DOI] [PubMed] [PMC]

82.

Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15:1243–53. [DOI] [PubMed] [PMC]

83.

Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98. [DOI] [PubMed]

84.

Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174–86. [DOI] [PubMed] [PMC]

85.

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–50. [DOI] [PubMed] [PMC]

86.

Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18:157. [DOI] [PubMed] [PMC]

87.

Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352:175–80. [DOI] [PubMed] [PMC]

88.

Lyssiotis CA, Kimmelman AC. Metabolic Interactions in the Tumor Microenvironment. Trends Cell Biol. 2017;27:863–75. [DOI] [PubMed] [PMC]

89.

Klein K, He K, Younes AI, Barsoumian HB, Chen D, Ozgen T, et al. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Front Immunol. 2020;11:573326. [DOI] [PubMed] [PMC]

90.

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399–416. [DOI] [PubMed] [PMC]

91.

Leblond MM, Zdimerova H, Desponds E, Verdeil G. Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. Cancers (Basel). 2021;13:4712. [DOI] [PubMed] [PMC]

92.

Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593:282–8. [DOI] [PubMed] [PMC]

93.

Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559–63. [DOI] [PubMed] [PMC]

94.

Liu N, Luo J, Kuang D, Xu S, Duan Y, Xia Y, et al. Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2α-mediated tumor progression. J Clin Invest. 2019;129:631–46. [DOI] [PubMed] [PMC]

95.

Semenza GL. Pharmacologic Targeting of Hypoxia-Inducible Factors. Annu Rev Pharmacol Toxicol. 2019;59:379–403. [DOI] [PubMed]

96.

Morrissey SM, Zhang F, Ding C, Montoya-Durango DE, Hu X, Yang C, et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 2021;33:2040–58.e10. [DOI] [PubMed] [PMC]

97.

Zhang Y, Yang H, Zhao J, Wan P, Hu Y, Lv K, et al. Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer. J Immunother Cancer. 2021;9:e001364. [DOI] [PubMed] [PMC]

98.

Netea-Maier RT, Smit JWA, Netea MG. Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship. Cancer Lett. 2018;413:102–9. [DOI] [PubMed]

99.

Xiang W, Shi R, Kang X, Zhang X, Chen P, Zhang L, et al. Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression. Nat Commun. 2018;9:2574. [DOI] [PubMed] [PMC]

100.

Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79:506–15. [DOI] [PubMed]

101.

Tufail M, Jiang CH, Li N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer. 2024;23:203. [DOI] [PubMed] [PMC]

102.

Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021;3:21–32. [DOI] [PubMed] [PMC]

103.

Chen X, Ma Z, Yi Z, Wu E, Shang Z, Tuo B, et al. The effects of metabolism on the immune microenvironment in colorectal cancer. Cell Death Discov. 2024;10:118. [DOI] [PubMed] [PMC]

104.

Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019;95:912–9. [DOI] [PubMed]

105.

Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20:516–31. [DOI] [PubMed] [PMC]

106.

Certo M, Tsai CH, Pucino V, Ho PC, Mauro C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21:151–61. [DOI] [PubMed]

107.

Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, et al. Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res. 2016;76:1381–90. [DOI] [PubMed] [PMC]

108.

Renner K, Bruss C, Schnell A, Koehl G, Becker HM, Fante M, et al. Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy. Cell Rep. 2019;29:135–50.e9. [DOI] [PubMed]

109.

Guan X, Hasan MN, Begum G, Kohanbash G, Carney KE, Pigott VM, et al. Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy. Cell Death Dis. 2018;9:1010. [DOI] [PubMed] [PMC]

110.

Xia H, Wang W, Crespo J, Kryczek I, Li W, Wei S, et al. Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity. Sci Immunol. 2017;2:eaan4631. [DOI] [PubMed] [PMC]

111.

Comito G, Iscaro A, Bacci M, Morandi A, Ippolito L, Parri M, et al. Lactate modulates CD4⁺T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis. Oncogene. 2019;38:3681–95. [DOI] [PubMed]

112.

Gudgeon N, Munford H, Bishop EL, Hill J, Fulton-Ward T, Bending D, et al. Succinate uptake by T cells suppresses their effector function via inhibition of mitochondrial glucose oxidation. Cell Rep. 2022;40:111193. [DOI] [PubMed] [PMC]

113.

Bell HN, Huber AK, Singhal R, Korimerla N, Rebernick RJ, Kumar R, et al. Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer. Cell Metab. 2023;35:134–49.e6. [DOI] [PubMed] [PMC]

114.

Ma S, Zhao Y, Lee WC, Ong LT, Lee PL, Jiang Z, et al. Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nat Commun. 2022;13:4118. [DOI] [PubMed] [PMC]

115.

Ai M, Budhani P, Sheng J, Balasubramanyam S, Bartkowiak T, Jaiswal AR, et al. Tumor hypoxia drives immune suppression and immunotherapy resistance. J Immunotherapy Cancer. 2015;3:P392. [DOI]

116.

Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018;128:5137–49. [DOI] [PubMed] [PMC]

117.

Bian Y, Li W, Kremer DM, Sajjakulnukit P, Li S, Crespo J, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 2020;585:277–82. [DOI] [PubMed] [PMC]

118.

Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell. 2016;167:829–42.e13. [DOI] [PubMed] [PMC]

119.

Leone RD, Zhao L, Englert JM, Sun IM, Oh MH, Sun IH, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366:1013–21. [DOI] [PubMed] [PMC]

120.

Byun JK, Park M, Lee S, Yun JW, Lee J, Kim JS, et al. Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity. Mol Cell. 2020;80:592–606.e8. [DOI] [PubMed]

121.

Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, et al. CD8⁺T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270–4. [DOI] [PubMed] [PMC]

122.

Ma X, Xiao L, Liu L, Ye L, Su P, Bi E, et al. CD36-mediated ferroptosis dampens intratumoral CD8⁺T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33:1001–12.e5. [DOI] [PubMed] [PMC]

123.

Ma X, Bi E, Lu Y, Su P, Huang C, Liu L, et al. Cholesterol Induces CD8⁺T Cell Exhaustion in the Tumor Microenvironment. Cell Metab. 2019;30:143–56.e5. [DOI] [PubMed] [PMC]

124.

Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531:651–5. [DOI] [PubMed] [PMC]

125.

Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, et al. CD8⁺T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40:365–78.e6. [DOI] [PubMed] [PMC]

126.

Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, et al. Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metab. 2018;28:87–103.e6. [DOI] [PubMed] [PMC]

127.

Guo D, Tong Y, Jiang X, Meng Y, Jiang H, Du L, et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα. Cell Metab. 2022;34:1312–24.e6. [DOI] [PubMed]

128.

Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017;18:1332–41. [DOI] [PubMed] [PMC]

129.

Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell. 2015;162:1217–28. [DOI] [PubMed] [PMC]

130.

Najjar YG, Menk AV, Sander C, Rao U, Karunamurthy A, Bhatia R, et al. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019;4:e124989. [DOI] [PubMed] [PMC]

131.

Jaiswal AR, Liu AJ, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, et al. Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res. 2020;8:1365–80. [DOI] [PubMed] [PMC]

132.

Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, et al. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. J Clin Oncol. 2024;42:3692–701. [DOI] [PubMed]

133.

Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, et al. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022;8:1411–8. [DOI] [PubMed] [PMC]

134.

Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20:1083–97. [DOI] [PubMed]

135.

Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, et al. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018;36:3223–30. [DOI] [PubMed] [PMC]

136.

Daud A, Saleh MN, Hu J, Bleeker JS, Riese MJ, Meier R, et al. Epacadostat plus nivolumab for advanced melanoma: updated phase 2 results of the ECHO-204 study. J Clin Oncol. 2018;36:9511. [DOI]

137.

Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, et al. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018;118:153–61. [DOI] [PubMed] [PMC]

138.

Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, et al. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clin Cancer Res. 2016;22:2848–54. [DOI] [PubMed] [PMC]

139.

Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, et al.; HALO 109-301 Investigators. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020;38:3185–94. [DOI] [PubMed] [PMC]

140.

Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115–26. [DOI] [PubMed]

141.

Ma J, Trinh RT, Mahant ID, Peng B, Matthias P, Heijnen CJ, et al. Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers. Pain. 2019;160:2877–90. [DOI] [PubMed] [PMC]

142.

Kuboki Y, Koyama T, Matsubara N, Naito Y, Kondo S, Harano K, et al. PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer Med. 2024;13:e6980. [DOI] [PubMed] [PMC]